Central neurotoxicity of immunomodulatory drugs in multiple myeloma

Urmeel H. Patel; Muhammad A. Mir; Jeffrey K. Sivik; Divisha Raheja; Manoj K. Pandey; Giampaolo Talamo

doi:10.4081/hr.2015.5704

Central neurotoxicity of immunomodulatory drugs in multiple myeloma

Urmeel H. Patel, Muhammad A. Mir, Jeffrey K. Sivik, Divisha Raheja, Manoj K. Pandey, Giampaolo Talamo

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was associated with various clinical manifestations of central neurotoxicity, including reversible coma, amnesia, expressive aphasia, and dysarthria. Central neurotoxicity should be recognized as an important side effect of IMiD therapy.

Original language	English (US)
Pages (from-to)	12-14
Number of pages	3
Journal	Hematology Reports
Volume	7
Issue number	1
DOIs	https://doi.org/10.4081/hr.2015.5704
State	Published - Mar 3 2015
Externally published	Yes

All Science Journal Classification (ASJC) codes

Hematology

Access to Document

10.4081/hr.2015.5704

Cite this

@article{c605a419fa264386870f8857a6d48c7a,

title = "Central neurotoxicity of immunomodulatory drugs in multiple myeloma",

abstract = "Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was associated with various clinical manifestations of central neurotoxicity, including reversible coma, amnesia, expressive aphasia, and dysarthria. Central neurotoxicity should be recognized as an important side effect of IMiD therapy.",

author = "Patel, {Urmeel H.} and Mir, {Muhammad A.} and Sivik, {Jeffrey K.} and Divisha Raheja and Pandey, {Manoj K.} and Giampaolo Talamo",

note = "Publisher Copyright: {\textcopyright} U.H. Patel et al., 2015.",

year = "2015",

month = mar,

day = "3",

doi = "10.4081/hr.2015.5704",

language = "English (US)",

volume = "7",

pages = "12--14",

journal = "Hematology Reports",

issn = "2038-8322",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "1",

}

TY - JOUR

T1 - Central neurotoxicity of immunomodulatory drugs in multiple myeloma

AU - Patel, Urmeel H.

AU - Mir, Muhammad A.

AU - Sivik, Jeffrey K.

AU - Raheja, Divisha

AU - Pandey, Manoj K.

AU - Talamo, Giampaolo

PY - 2015/3/3

Y1 - 2015/3/3

N2 - Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was associated with various clinical manifestations of central neurotoxicity, including reversible coma, amnesia, expressive aphasia, and dysarthria. Central neurotoxicity should be recognized as an important side effect of IMiD therapy.

AB - Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was associated with various clinical manifestations of central neurotoxicity, including reversible coma, amnesia, expressive aphasia, and dysarthria. Central neurotoxicity should be recognized as an important side effect of IMiD therapy.

UR - http://www.scopus.com/inward/record.url?scp=84982730394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982730394&partnerID=8YFLogxK

U2 - 10.4081/hr.2015.5704

DO - 10.4081/hr.2015.5704

M3 - Article

AN - SCOPUS:84982730394

SN - 2038-8322

VL - 7

SP - 12

EP - 14

JO - Hematology Reports

JF - Hematology Reports

IS - 1

ER -

Central neurotoxicity of immunomodulatory drugs in multiple myeloma

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this